takeaway barclay ca medtool bu tour
tuesday host group meet headquart ith cfo ad overal meet help build
comfort recent guidanc reset clear deck area major investor uncertainti meet
includ discuss popul sequenc clinic direct-to-consum test compani competit posit
thought earn pleas see inc major new issu full print
also host barclay premier event ith tw industri expert focus et nyc ebcast
region detail regist pleas see barclay equiti premier event tool expert lunch focu next-gener
samad discuss popul sequenc major opportun compani despit short term nois relat
project time right popul sequenc still small part busi size hsd percentag revenu
time compani think sampl could sequenc initi current contempl across countri
near term sever notabl project focu though pipelin expect diversifi build time
samad ad mani countri current variou stage readi exampl uk appear advanc given
complet genom england project hich transit broader program manag nh system addit
us initi nih us lot effort put format ith enrol individu
select three center ho prepar data gener said coordin remain done
delay contribut decis reset expect cfo samad note new guidanc take
much cautiou approach popul sequenc given unpredict time ork ith govern
stakehold group coordin ith govern provid bulk discount consist ith given
commerci custom exampl samad highlight us initi origin assum genom ould
sequenc year though push believ consum alon delay could
impact compani guidanc expect popul sequenc initi drive instrument
consum sale compani versu gel project hich earn servic revenu ith uk
expect clinic test import area growth cfo samad ad build new categori hich
 ere envis hen compani laid total address market sever year ago includ liquid biopsi
averag risk nipt compani see much opportun number differ test categori includ oncolog nipt
rare undiagnos diseas one emerg area compani ad ould pharmacogenet though also see
adopt area microbiolog infecti diseas focus develop end-to-end platform address
diagnost custom base think true sample-to-answ er solut ould game changer broaden adopt ith
clinic custom compani veriseq orkflow nipt oncolog kit good exampl compani
look broaden adopt ith clinic custom attempt place desktop sequenc platform small mid-
size hospit said also attempt penetr commun set sequenc done premis
introduc ivd kit pleas see thought tool kit volume issu perspect diagnost fund
applic
direct consum test dtc
rapid declin dtc test surpris industri think new guidanc take much
risk associ categori remind low ere guidanc microarray grow th
predominantli due dtc eak compani initi forecast msd grow th low ere
forecast flat grow th y/i said remain bullish long-term opportun dtc especi health
applic addit dtc continu grow intern though still much room penetr
expect acquisit pacbio cover close though remain depend rule
multipl regulatori bodi look ahead remain discuss ith ftc phase review ith
 hich goe samad describ pacbio complimentari acquisit ith overlap custom technolog high-
throughput custom imposs replac speed cost accuraci short-read sequenc mention hile
long-read sequenc import certain applic market still small technolog compani believ
combin long short read technolog ill optim custom ultim custom feedback posit
prospect acquisit complementari merger reason disagre
complimentari deal expect close acknowledg limit insight view regul
acquisit current built forecast pleas see inc complement grow th
long read ith pacbio strateg pleas also see custom feedback posit propos
samad note instrument placement ahead schedul except larg delay order
importantli reiter commentari novaseq placement expect flat-to-up addit novaseq low er
throughput sequenc remain import part strategi compani record nextseq placement
desktop sequenc import clinic set ell introductori platform mani custom
major focu novaseq placement import note revenu recur natur fact
revenu deriv consum servic
cfo samad weigh competit landscap well compani on-going litig bgi samad note
compani alw ay go competit compani confid technolog commerci capabl samad
ad complex eb ip protect ensur safeti technolog ip roll ip begin
kick partial driven innov new product launch
follow ing low ere revenu guidanc manag activ low ere expens importantli samad note compani
cut cost instead focu discretionari expens includ contractor consult spend
pleas reach us ith question thank
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens ill
directli indirectli relat specif recommend view express research report
barclay capit inc and/or one affili seek busi ith compani cover research report
result investor aw firm may conflict interest could affect object report investor
consid report singl factor make invest decis
barclay research produc invest bank barclay bank plc affili collect individu
barclay author contribut research report research analyst unless otherw ise indic public date
top report reflect local time report produc may differ releas date provid gmt
avail disclosur
 compani subject research report current import disclosur regard compani pleas
refer http //publicresearch barclay com altern send ritten request barclay research complianc seventh
avenu floor new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ
firm total revenu portion hich gener invest bank activ profit revenu market
busi potenti interest firm invest client research ith respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit
accept payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link
analysi quantit analysi trade idea recommend contain one type barclay research may differ
contain type barclay research hether result differ time horizon methodolog otherw ise
order access barclay statement regard research dissemin polici procedur pleas refer
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas
refer http //publicresearch barcap com/s/cm htm
master limit partnership mlp pass-through entiti structur publicli list partnership tax purpos
distribut unit holder may treat return princip investor consult ow tax advisor
invest unit
valuat methodolog price target repres pro-forma ep hich includ stand-alon
ep forecast ell potenti pacbio dilut stand-alon forecast exclud pacbio acquisit
transact close expect late target multipl base histor ratio earn grow th
project high-teen forseeabl futur
risk may imped achiev barclay research valuat price given pace innov
cycl next gener sequenc believ incumb maintain high level innov extend
advantag versu peer addit long-read sequenc technolog could disrupt advantag short-read
sequenc final given nascent opportun clinic remain potenti greater competit risk
rate price target histori
prior intra-day chang may publish rate secur equal eight
adjust price target
histor stock price price target may adjust stock split dividend
price sourc refinitiv last avail close price relev trade market unless anoth time sourc
indic
